Northern Ireland strikes deal for access to triple combination therapy
The deal with Vertex Pharmaceuticals gives access to people with CF in Northern Ireland, aged 12 and over with two copies of the F508del mutation, or one copy of F508del and one copy of a 'minimal function mutation'.
The announcement comes after similar deals in England and Wales. This is a big moment for the CF community who have campaigned tirelessly alongside the Trust for access to life-saving drugs.
Dr Keith Brownlee, Director of Policy, Programmes & Support at the Cystic Fibrosis Trust, said: “We’re delighted to see Northern Ireland and Vertex Pharmaceuticals reach a deal on Kaftrio, ensuring that hundreds of people across Northern Ireland will soon get access to this truly life-saving medicine.
“While this is a special moment, there is more to do, and we will not stop until everyone with cystic fibrosis across the UK has access to life saving drugs.”
Liam McHugh, aged 58 from County Tyrone in Northern Ireland said: “My daughter Rachel was born with cystic fibrosis over 28 years ago and ever since I've dedicated my life to fundraising and campaigning for life-saving drugs for people with the condition. So news that Kaftrio will be available to people in Northern Ireland is incredible and is going to extend lives.”
The Trust will continue to fight for everyone living with CF, regardless of their genotype. Donate now to support this vital work, and find out more about what licensing the triple therapy means for you.